Alcohol and tobacco consumption are closely correlated and published results on their association with breast cancer have not always allowed adequately for confounding between these exposures. Over 80% of the relevant information worldwide on alcohol and tobacco consumption and breast cancer were collated, checked and analysed centrally. Analyses included 58 515 women with invasive breast cancer and 95 067 controls from 53 studies. Relative risks of breast cancer were estimated, after stratifying by study, age, parity and, where appropriate, women's age when their first child was born and consumption of alcohol and tobacco. The average consumption of alcohol reported by controls from developed countries was 6.0 g per day, i.e. about half a unit/drink of alcohol per day, and was greater in ever-smokers than never-smokers, (8.4 g per day and 5.0 g per day, respectively). Compared with women who reported drinking no alcohol, the relative risk of breast cancer was 1.32 (1.19 -1.45, P50.00001) for an intake of 35 -44 g per day alcohol, and 1.46 (1.33 -1.61, P50.00001) for 545 g per day alcohol. The relative risk of breast cancer increased by 7.1% (95% CI 5.5 -8.7%; P50.00001) for each additional 10 g per day intake of alcohol, i.e. for each extra unit or drink of alcohol consumed on a daily basis. This increase was the same in ever-smokers and never-smokers (7.1% per 10 g per day, P50.00001, in each group). By contrast, the relationship between smoking and breast cancer was substantially confounded by the effect of alcohol. When analyses were restricted to 22 255 women with breast cancer and 40 832 controls who reported drinking no alcohol, smoking was not associated with breast cancer (compared to never-smokers, relative risk for ever-smokers=1.03, 95% CI 0.98 -1.07, and for current smokers=0.99, 0.92 -1.05). The results for alcohol and for tobacco did not vary substantially across studies, study designs, or according to 15 personal characteristics of the women; nor were the findings materially confounded by any of these factors. If the observed relationship for alcohol is causal, these results suggest that about 4% of the breast cancers in developed countries are attributable to alcohol. In developing countries, where alcohol consumption among controls averaged only 0.4 g per day, alcohol would have a negligible effect on the incidence of breast cancer. In conclusion, smoking has little or no independent effect on the risk of developing breast cancer; the effect of alcohol on breast cancer needs to be interpreted in the context of its beneficial effects, in moderation, on cardiovascular disease and its harmful effects on cirrhosis and cancers of the mouth, larynx, oesophagus and liver. Many epidemiological studies have investigated the relationship between breast cancer and the consumption of alcohol and/or tobacco. References to over 80 studies that have collected relevant data, as well as to reviews of the subject, are given in Appendix II (www. bjcancer.com). The published results from these studies have general...
Summary.-Follicular-phase (Day 11) plasma prolactin, and plasma and urinary oestrogen levels of 70 nulliparous nuns were compared with those of 80 of their sisters, of whom 62 were parous. The nuns and their nulliparous sisters did not differ significantly in their prolactin and oestrogen levels. No differences in plasma oestrogens or urinary oestriol ratio were found between the parous and the nulliparous women. However, the mean prolactin level of the nuns and their nulliparous sisters was 3500 higher than that of the parous women in the sample taken 13 h after rising (P < 0-0005), and 24% higher (P <0.01) in the 2nd sample taken 2 h later. The elevation was independent of age, weight, and age at menarche. Age at first full-term pregnancy, at least up to the age of 30, and second or subsequent full-term pregnancies had no further effect on prolactin level. This study suggests that the effect of early first full-term pregnancy in lowering breast cancer risk may be mediated, at least in part, by permanently lowering the level of circulating prolactin.ONE OF THE MOST STRIKING breastcancer risk factors is age at first full-term pregnancy (FFTP): women whose FFTP is before the age of 20 have less than half the breast-cancer risk of nulliparous women (MacMahon et al., 1973). Two theories have been proposed to "explain" how this protective effect of early FFTP is brought about. Cairns (1975) theorized that early FFTP would effectively reduce the number of susceptible breast "stem" cells, while Cole et al. (1976) proposed that the protective effect may be due to a change in the "urinary oestriol ratio". There is no evidence available to either support or refute Cairns's hypothesis, but there is some evidence that early FFTP does increase the urinary oestriol ratio (Cole et al., 1976;Trichopoulos et al., 1980).Prolactin may also play a key role in determining risk of breast cancer (Hill et al., 1976;Malarkey et al., 1977;Pike et al., 1977;Welsch & Meites, 1978) and we were struck by the finding of Vekemans & Robyn (1 975a) in a cross-sectional study that prolactin levels decreased after age 25 in women but not in men. If this decrease with age in women is due to pregnancy, this prolactin change may be a critical part of the protective effect of early FFTP.In this paper we describe our results in comparing the plasma prolactin, and plasma and urinary oestrogen levels of nulliparous and parous women aged in California. METHODSWith the cooperation of a number of Catholic orders in California, we identified Caucasian nuns aged 20-39, who had never been pregnant and who had at least one sister aged 20-39 residing in the continental U.S. We excluded nuns who had had uterine (excluding D&C) or ovarian surgery. We also
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.